bismuth subsalicylate 262 MG Chewable Tablet [Pepto-bismol]

Known as: BISMUTH SUBSALICYLATE 262 mg ORAL TABLET, CHEWABLE [Pepto Bismol], Pepto-Bismol InstaCool 262 MG Chewable Tablet, BISMUTH SUBSALICYLATE 262 mg ORAL TABLET [Pepto-Bismol To Go] 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1975-2017
02419752017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
Bismuth subsalicylate (BSS), the active ingredient of Pepto-Bismol, has been used for many years to treat various disorders of… (More)
  • table 1
  • table 2
Is this relevant?
2004
2004
BACKGROUND Quadruple therapy provided inadequate eradication rate when given twice-a-day at breakfast and evening meals. AIM To… (More)
Is this relevant?
2001
2001
UNLABELLED A controlled, randomized, double-blind study in Bangladeshi children (ages 4-36 mo) with acute diarrhoea was… (More)
Is this relevant?
1999
1999
Resnik E, LeFevre CA. Fulminant Clostridium difficile colitis associated with paclitaxel and carboplatin chemotherapy… (More)
Is this relevant?
1997
1997
RATIONALE Bismuth subsalicylate, tetracycline hydrochloride, and metronidazole are widely used in combination for the treatment… (More)
Is this relevant?
1992
1992
We evaluated clindamycin and bismuth subsalicylate (Pepto-Bismol) for treatment of Helicobacter pylori infection. Patients with… (More)
Is this relevant?
1992
1992
The effects of sublethal concentrations of bismuth salts on bacterial invasion of mammalian cells were investigated. Pepto-Bismol… (More)
  • table 1
  • figure 3
  • figure 4
Is this relevant?
1991
1991
To determine whetherHelicobacter pylori has an effect on gastroduodenal mucosal prostaglandin generation, mucosal biopsies were… (More)
  • table 1
  • figure 1
Is this relevant?
1990
1990
The antisecretory properties of Pepto-Bismol (PB) and its active ingredient, bismuth subsalicylate (BSS), were studied in ligated… (More)
Is this relevant?